A phase II study of weekly irinotecan as first-line therapy for patients with metastatic pancreatic cancer

Keywords

IrinotecanPancreatic cancerMedicineGemcitabineOncologyInternal medicineCancerPhases of clinical researchChemotherapyColorectal cancer

Affiliated Institutions

Related Publications

Irinotecan Plus Gemcitabine Results in No Survival Advantage Compared With Gemcitabine Monotherapy in Patients With Locally Advanced or Metastatic Pancreatic Cancer Despite Increased Tumor Response Rate

Caio M. Rocha Lima , Mark R. Green , Robert Rotche +7 more

Purpose This phase III, randomized, open-label, multicenter study compared the overall survival associated with irinotecan plus gemcitabine (IRINOGEM) versus gemcitabine monothe...

2004 Journal of Clinical Oncology 579 citations

Phase III, Randomized Study of Gemcitabine and Oxaliplatin Versus Gemcitabine (fixed-dose rate infusion) Compared With Gemcitabine (30-minute infusion) in Patients With Pancreatic Carcinoma E6201: A Trial of the Eastern Cooperative Oncology Group

Elizabeth Poplin , Yang Feng , Jordan Berlin +9 more

Purpose Single-agent gemcitabine (GEM) is standard treatment of metastatic pancreatic cancer. Fixed-dose rate (FDR) GEM and GEM plus oxaliplatin have shown promise in early clin...

2009 Journal of Clinical Oncology 423 citations

Gemcitabine in Combination With Oxaliplatin Compared With Gemcitabine Alone in Locally Advanced or Metastatic Pancreatic Cancer: Results of a GERCOR and GISCAD Phase III Trial

Christophe Louvet , Roberto Labianca , Pascal Hammel +10 more

Purpose Gemcitabine (Gem) is the standard treatment for advanced pancreatic cancer. Given the promising phase II results obtained with the Gem-oxaliplatin (GemOx) combination, w...

2005 Journal of Clinical Oncology 945 citations

Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)

Hedy L. Kindler , Donna Niedzwiecki , Donna Hollis +12 more

Purpose The combination of gemcitabine plus bevacizumab produced a 21% response rate and a median survival of 8.8 months in a multicenter phase II trial in patients with metasta...

2010 Journal of Clinical Oncology 834 citations

Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1

Giuseppe Giaccone , Roy S. Herbst , Christian Manegold +15 more

Purpose The purpose of this study was to determine whether the addition of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839; AstraZeneca,...

2004 Journal of Clinical Oncology 1718 citations

Publication Info

Year: 2006
Type: article
Volume: 59
Issue: 4
Pages: 447-454
Citations: 60
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

A phase II study of weekly irinotecan as first-line therapy for patients with metastatic pancreatic cancer

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

OpenAlex

Cite This

APA Style

                            
                                
                                    Hideki Ueno, 
                                
                                    Takuji Okusaka, 
                                
                                    Akihiro Funakoshi
                                
                                et al.
                            
                            (2006). 
                            A phase II study of weekly irinotecan as first-line therapy for patients with metastatic pancreatic cancer. 
                            Cancer Chemotherapy and Pharmacology
                            , 59
                            (4)
                            , 447-454.
                            https://doi.org/10.1007/s00280-006-0283-9
                        

Identifiers

DOI: 10.1007/s00280-006-0283-9